Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimera??s Disease at CTAD 2019

- New Data Shows Clinical Evidence of Target Engagement and Target Validation a??
- Company Expects Data Publication in a Peer-reviewed Medical Journal a??AUSTIN, Texas, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biopharmaceutical company focused on Alzheimera??s disease, today announced additional clinical data from a Phase 2a study of PTI-125, its investigational drug candidate for Alzheimera??s disease.A  Company scientists presented the new data during a late-breaking oral presentation today at the 12th International Conference on Clinical Trials on Alzheimera??s Disease (CTAD), in San Diego, Ca.A  Consistent with over 10 years of basic research and pre-clinical data, the new data show clinical evidence of PTI-125a??s mechanism of action and drug-target engagement, including:

Improvements in biomarkers of Alzheimera??s disease in plasma and lymphocytes;

Consistency across biomarker improvements in CSF, plasma, and lymphocytes;

Significant reductions (p<0.01) in both nitrated and phosphorylated forms of tau protein;

Evidence that each individual patient showed biomarker responses to PTI-125;

Evidence that PTI-125 reversed the shape of altered filamin A in lymphocytes;

Early clinical validation of the drug target a?? altered filamin A a?? as a facilitator protein between amyloid beta and both neuroinflammation and tau pathology.

Cassava Sciences expects to publish a manuscript of these new clinical data in a peer-reviewed medical journal.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »